Related Experiment Video
Updated: Jan 23, 2026

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
Published on: February 20, 2017
Oestrogen Non-Genomic Signalling is Activated in Tamoxifen-Resistant Breast Cancer
Coralie Poulard1,2,3, Julien Jacquemetton4,5,6, Olivier Trédan7,8,9,10
1Université de Lyon, F-69000 Lyon, France. coralie.poulard@lyon.unicancer.fr.
Abstract:
Endocrine therapies targeting oestrogen signalling have significantly improved breast cancer management. However, their efficacy is limited by intrinsic and acquired resistance to treatment, which remains a major challenge for oestrogen receptor α (ERα)-positive tumours. Though many studies using in vitro models of endocrine resistance have identified putative actors of resistance, no consensus has been reached. We demonstrated previously that oestrogen non-genomic signalling, characterized by the formation of the ERα/Src/PI3K complex, is activated in aggressive breast cancers (BC). We wondered herein whether the activation of this pathway is also involved in resistance to endocrine therapies. We studied the interactions between ERα and Src or PI3K by proximity ligation assay (PLA) in in-vitro and in-vivo endocrine therapy-resistant breast cancer models. We reveal an increase in ERα/Src and ERα/PI3K interactions in patient-derived xenografts (PDXs) with acquired resistance to tamoxifen, as well as in tamoxifen-resistant MCF-7 cells compared to parental counterparts. Moreover, no interactions were observed in breast cancer cells resistant to other endocrine therapies. Finally, the use of a peptide inhibiting the ERα-Src interaction partially restored tamoxifen sensitivity in resistant cells, suggesting that such components could constitute promising targets to circumvent resistance to tamoxifen in BC.
Insights
Oestrogen receptor alpha (ERα) interactions with Src and PI3K increase in tamoxifen-resistant breast cancer. Inhibiting ERα-Src interactions may restore tamoxifen sensitivity, offering new therapeutic strategies for endocrine resistance.
Area of Science:
- Oncology
- Endocrinology
- Molecular Biology
Background:
- Endocrine therapies targeting oestrogen signalling are crucial for ERα-positive breast cancer.
- Treatment resistance remains a significant clinical challenge, limiting therapeutic efficacy.
- Non-genomic oestrogen signalling via the ERα/Src/PI3K complex is implicated in aggressive breast cancer.
Purpose of the Study:
- To investigate the role of ERα/Src/PI3K pathway activation in endocrine therapy resistance.
- To determine if ERα interactions with Src and PI3K are altered in tamoxifen-resistant breast cancer models.
- To explore the therapeutic potential of targeting ERα-Src interactions to overcome resistance.
Main Methods:
- Proximity Ligation Assay (PLA) to study ERα interactions with Src and PI3K.
- Utilized in vitro (MCF-7 cells) and in vivo (patient-derived xenografts) models of tamoxifen resistance.
- Tested a peptide inhibitor targeting the ERα-Src interaction.
Main Results:
- Increased ERα/Src and ERα/PI3K interactions were observed in tamoxifen-resistant breast cancer models (MCF-7 cells and PDXs).
- These specific interactions were not elevated in resistance to other endocrine therapies.
- A peptide inhibiting ERα-Src interaction partially restored sensitivity to tamoxifen in resistant cells.
Conclusions:
- Activation of ERα/Src and ERα/PI3K signalling pathways is associated with acquired tamoxifen resistance in breast cancer.
- The ERα-Src interaction represents a potential therapeutic target to circumvent tamoxifen resistance.
- Targeting this pathway could offer novel strategies for managing endocrine-resistant breast cancer.
Related Concept Videos
Treatment Resistant Cancers
Genomics
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Genomic Imprinting and Inheritance
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...
Genome Size and the Evolution of New Genes
Resistivity

